The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Jul. 30, 7:07 AM

Slide #22. CymaBay Therapeutics, Inc. Secondary Offering

Company: CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
Date announced: 7/17/2014
Shares Offered: 4,000,000
Date of Pricing: 7/22/2014
Price Per Share: $5.50
Secondary Offering Details: CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it has commenced an underwritten public offering of 3,500,000 shares of its common stock. The company expects to grant the underwriter a 30-day option to purchase up to an additional 525,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by CymaBay Therapeutics. - updated 7/22 - CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced the pricing of its follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $5.50 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by CymaBay Therapeutics. In addition, CymaBay Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price less the underwriting discounts and commissions to cover over-allotments, if any. The company's shares are traded on The NASDAQ Capital Market under the ticker symbol "CBAY". The offering is expected to close on July 25, 2014, subject to customary closing conditions.

Cymabay Therapeutics is a biopharmaceutical company engaged in discovering and developing therapies to treat metabolic diseases and gout. Arhalofenate, Co.'s lead product candidate, is being developed for the treatment of gout. Arhalofenate has demonstrated two therapeutic actions: the prevention of painful attacks of gout in joints (flares) and the lowering of serum uric acid (sUA) by promoting excretion of uric acid by the kidney.
Open the CBAY Page at The Online Investor »

Company Name:  CymaBay Therapeutics Inc
Website:  www.cymabay.com
Sector:  Drugs & Pharmaceuticals
 

Open the CBAY Page at The Online Investor (in a new window) »

July 30, 2014    7:07 AM Eastern
Quotes delayed 20 minutes


Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.